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Abstract
Background: Tetanus-reduced dose diphtheria-acellular pertussis (Tdap) vaccination during adolescence was
introduced in response to the resurgence of pertussis in various countries. A new Tdap vaccine was manufactured
in Korea as a countermeasure against a predicted Tdap vaccine shortage. This study was performed to evaluate the
immunogenicity, safety, and protection efficacy against Bordetella pertussis of the new Tdap vaccine in a murine
model.
Methods: Four-week-old BABL/c mice were used for assessment of immunogenicity and protection efficacy. A
single dose of primary diphtheria-tetanus-acellular pertussis (DTaP) vaccine was administered, followed by a single
dose of Tdap booster vaccine after a 12-week interval. Anti-pertussis toxin (PT), anti-filamentous hemagglutinin
(FHA), and anti-pertactin (PRN) IgG titers were measured before primary vaccination, and before and after booster
vaccination. An intranasal challenge test was performed after booster vaccination to determine protection efficacy.
To assess safety, mouse weight gain test and leukocytosis promotion test were performed using 4-week-old ddY
female mice.
Results: Anti-PT and anti-FHA IgG titers after booster vaccination were significantly higher than those before
booster vaccination with either the new vaccine or a commercially available Tdap vaccine (P = 0.01 for all
occasions). After booster vaccination, no significant difference was observed between the two vaccines in antibody
titers against pertussis antigens (P = 0.53 for anti-PT IgG, P = 0.91 for anti-FHA IgG, P = 0.39 for anti-PRN IgG). In the
intranasal challenge test, inoculated B. pertussis was eradicated 7 days after infection. On days 4 and 7 after
infection, colony counts of B. pertussis were not significantly different between the new and positive control
vaccine groups (P = 1.00). Mean body weight changes and leukocyte counts of the new vaccine, positive control,
and negative control groups were not significantly different 7 days after vaccination (P = 0.87 and P = 0.37,
respectively). All leukocyte counts in the new vaccine group were within a mean ± 3 standard deviations range.
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Conclusions: A murine model involving a single dose primary DTaP vaccination followed by a single dose Tdap
booster vaccination can be used for non-clinical studies of Tdap vaccines. The new Tdap vaccine manufactured in
Korea exhibited comparable immunogenicity, protection efficacy, and safety with a commercially available Tdap
vaccine.
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Background
Bordetella pertussis is the causative agent of pertussis,
which is characterized by a paroxysmal cough, and may
lead to severe complications and mortality [1, 2]. Occur-
rence of pertussis has decreased since the introduction
of the diphtheria-tetanus-whole cell pertussis (DTwP)
vaccine in the 1950s, which contains pertussis antigens
as well as diphtheria and tetanus toxoids [1]. The
diphtheria-tetanus-acellular pertussis (DTaP) vaccine
was later developed to reduce the severe adverse effects
associated with pertussis antigens included in the DTwP
vaccine [3]. In Korea, DTaP vaccines have replaced
DTwP vaccines since 1985 [4], and in other western
countries, DTaP vaccines have been administered since
the 1990s [1, 5]. However, resurgence of pertussis was
observed in various western countries after then [1, 2,
5], and it has also been observed in Korea since the
2000s [4]. Such resurgence of pertussis is believed to be
a consequence of waning immunity against pertussis ac-
quired by DTaP vaccination, and therefore, a booster
vaccination with a tetanus-reduced dose diphtheria-
acellular pertussis (Tdap) vaccine during adolescence
was introduced [6, 7]. In anticipation of a predicted
Tdap vaccine shortage, the Green Cross Corporation
(GCC; Yongin, Korea), a pharmaceutical company of
Korea, developed a new Tdap vaccine [8].
The World Health Organization (WHO) recommends
conducting non-clinical trials for newly developed vac-
cines containing acellular pertussis (aP) antigens, if the
vaccine contains a novel antigen or is manufactured by a
new manufacturer, new process, or new strain [9]. We
previously reported the immunogenicity and protection
efficacy of the newly developed GCC Tdap vaccine in a
murine model in 2015, and demonstrated that the new
vaccine showed comparable efficacy with a commercially
available Tdap vaccine [8]. However, in the previous study,
a robust antibody response was observed after two doses
of primary DTaP vaccination, which prevented differenti-
ation of the effects of the Tdap booster vaccine [8].
The present study was performed to evaluate the im-
munogenicity, protection efficacy, and safety of the new
GCC Tdap vaccine in a murine model, using a strategy
that addressed the limitations of the previous study. This
study will assist in the establishment of future non-
clinical trials on Tdap vaccines.
Methods
Assessment of immunogenicity
Four-week-old BALB/c female mice were acquired from
Orientbio Co. Ltd. (Seongnam, Republic of Korea), and
the mice were housed under semi-specific pathogen-free
conditions with food and water available ad libitum. A
single dose of DTaP vaccine was administered as the pri-
mary vaccination, and Tdap booster vaccination was
performed 12 weeks later. The mice were divided into
five groups according to the primary and booster vac-
cines administered (Table 1). Group 1 mice were
injected with phosphate-buffered saline (PBS) as both
primary and booster vaccines, and Group 2 mice were
administered with DTaP vaccine (Infanrix®, GlaxoS-
mithKlein, Middlesex, UK) as the primary vaccination
and PBS as the booster vaccination. Primary DTaP vac-
cination and booster tetanus-reduced dose diphtheria
(Td) vaccination were administered to mice in Group 3.
Those in Groups 4 and 5 received primary DTaP vaccin-
ation, and either the new GCC Tdap vaccine (Group 4)
or a commercially available Tdap vaccine (Boostrix®,
GlaxoSmithKlein; Group 5) as the booster vaccination.
The GCC Tdap vaccine and Boostrix® contained identi-
cal doses of pertussis antigens: pertussis toxin (PT) 8 μg,
filamentous hemagglutinin (FHA) 8 μg and pertactin
(PRN) 2.5 μg within 0.5 mL. One-fourth the human dose
(0.125 mL) was injected intraperitoneally for all vaccines
and PBS as like previous murine model studies on the
immunogenicity of aP vaccines [10–12].
The immunogenicity of vaccines was evaluated by
measuring antibody titers against three pertussis antigens
(anti-PT IgG, anti-FHA IgG and anti-PRN IgG) using
commercially available enzyme-linked immunosorbent
Table 1 Characteristics of study groups
Group Primary vaccine Booster vaccine
Group 1 Phosphate-buffered saline Phosphate-buffered saline
Group 2 DTaP Phosphate-buffered saline
Group 3 DTaP Td
Group 4 DTaP Tdap (new GCC vaccine)
Group 5 DTaP Tdap (positive control vaccine)
DTaP diphtheria-tetanus-acellular pertussis, GCC Green Cross Corporation,
Td tetanus-reduced dose diphtheria, Tdap tetanus-reduced dose
diphtheria-acellular pertussis.
Kwon et al. BMC Infectious Diseases  (2017) 17:247 Page 2 of 8
assay (ELISA) kits (Alpha Diagnostic International Inc.,
San Antonio, TX, USA). Blood samples were collected
from the retro-bulbar venous plexuses of 10 mice in each
group before primary vaccination, immediately before
booster vaccination, and 3 weeks after booster vaccin-
ation. Anti-diphtheria toxoid (DT) IgG and anti-tetanus
toxoid (TT) IgG titers were also measured using commer-
cially available ELISA kits (Alpha Diagnostic International
Inc.). Antibody titers of each tested antigen were com-
pared between mice groups at each timepoint, and titers
before and after booster vaccination were compared
within each group.
Intranasal challenge test
The protection efficacy against B. pertussis infection was
evaluated using an intranasal challenge test in Groups 2,
4, and 5. A B. pertussis strain obtained from a Korean
adult pertussis patient, which was supplied from the Ko-
rean Centers for Disease Control & Prevention (No.
13674), was intranasally inoculated at 6 × 106 colony
forming units (CFUs) 4 weeks after booster vaccination.
Considering that the emergence of genetically mutated
B. pertussis strains escaping from vaccine effects was
proposed to be a cause of resurgence of pertussis in re-
cent years [13], the vaccine effect on the B. pertussis
strain isolated from a pertussis patient rather than vac-
cine strain could be more reliable in the real world. Five
mice in each group were sacrificed and their lungs were
extracted 2 h, 2 days, 4 days, 7 days, and 9 days after in-
tranasal infection. The lungs were homogenized in
10 mL of PBS, and the homogenates were diluted to
concentrations of 10−1, 10−3, and 10−5. Each diluted
homogenate was incubated on a Bordet-Gengou agar
plate at 36 °C for 4 days. CFUs of cultured B. pertussis
on each agar plate were then determined, and mean
CFUs were compared between mice groups at each
timepoint.
Assessment of safety
Mouse weight gain test (MWGT) and leukocytosis pro-
motion (LP) test were performed to determine the safety
of the GCC Tdap vaccine. Four-week-old ddY female
mice (Orientbio Co. Ltd.), which were used in a previous
study on the safety assessment of aP vaccines [14], were
also used in the present study. Three groups of 10 mice
were intraperitoneally inoculated with the GCC Tdap
vaccine (test group), a commercially available Tdap vac-
cine (Boostrix®, positive control group), and PBS (nega-
tive control group), respectively. Each vaccine was
administered at 25% of the human dose (0.125 mL). The
mice were weighed before vaccination and 1, 2, 5, 6, and
7 days after vaccination. The mean body weights of the
three groups were compared at each timepoint, and the
vaccine was considered to be non-toxic if the mean body
weight gain of the vaccinated group exceeded 60% of
that of the negative control group 7 days after
vaccination.
For the LP test, leukocyte counts were determined
from tail vein blood samples collected 7 days after vac-
cination. Because the exact pass criteria for the LP test
have not been established, leukocyte counts were simply
compared between groups, and test group values were
assessed to determine whether they fell consistently
within the range of mean ± 3 standard deviations (SDs)
for assessing the assay validity [15].
Statistical analysis
Antibody titers in Groups 1 to 5 were compared using a
Kruskal-Wallis test at each sampling timepoint. To as-
sess immunogenicity for each group, antibody titers be-
fore and after booster vaccination were compared using
a Wilcoxon signed rank test. For the intranasal challenge
test, CFU values of B. pertussis in the lungs of GCC vac-
cinated and positive and negative control mice were
compared using a Kruskal-Wallis test at each timepoint.
For the safety assessment, mean body weights at each
timepoint and leukocyte counts 7 days after vaccination
were compared between groups using a one-way analysis
of variance test. Statistical analysis was performed using
SPSS Statistics version 18.0 (SPSS Inc., Chicago, IL,
USA), and statistical significance was defined as a two-
tailed P value<0.05.
Results
Immunogenicity of the Tdap vaccine
IgG titers against pertussis antigens before primary vac-
cination were not significantly different among the five
groups (P = 0.07 for anti-PT IgG, P = 0.57 for anti-FHA
IgG, P = 0.91 for anti-PRN IgG, Fig. 1). Prior to booster
vaccination, anti-PT IgG (P < 0.01) and anti-FHA IgG
(P < 0.01) titers in Group 1 were significantly lower than
all other groups. After booster vaccination, anti-PT IgG
and anti-FHA IgG titers significantly increased in Group
4 (P = 0.01, P = 0.01, respectively) and Group 5
(P = 0.01, P = 0.01, respectively). However, no significant
differences were observed in anti-PRN IgG titers before
and after booster vaccination in these groups. There was
no significant difference in anti-PT IgG, anti-FHA IgG,
and anti-PRN IgG titers between the Groups 4 and 5
after booster vaccination (Fig. 1).
Anti-DT IgG (P = 0.54) and anti-TT IgG (P = 0.41) ti-
ters were not significantly different among the five
groups before primary vaccination, and titers in Groups
2 to 5 were significantly higher than that in Group 1
after primary DTaP vaccination (P < 0.01, P = 0.01, re-
spectively, Fig. 2). After booster vaccination, anti-DT
IgG (P < 0.01) and anti-TT IgG (P < 0.01) titers in
Groups 3 to 5 were significantly higher than in Groups 1
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and 2. Among Groups 3 to 5, anti-TT IgG titers after
booster vaccination were not significantly different
(P = 0.34); however, the anti-DT IgG titer in Group 3
was significantly higher than in Groups 4 and 5 after
booster vaccination (P = 0.04).
Protection efficacy of the Tdap vaccine
On the day of intranasal challenge, colony counts of B.
pertussis in the lungs were not significantly different be-
tween Groups 2, 4, and 5 (Fig. 3). However, on days 2, 4,
and 7 after intranasal challenge, CFUs of Groups 4 and
5 were significantly lower than that of Group 2
(P < 0.01, P = 0.01, P < 0.01, respectively). Colony
counts 2 days after infection showed a significant differ-
ence between Groups 4 and 5 (P = 0.02); however, no
significant differences were observed at any subsequent
timepoints.
Safety of the Tdap vaccine
Mean body weights of the GCC vaccinated, positive con-
trol and negative control groups showed no significant
differences prior to vaccination, and mean body weight
changes assessed 1, 2, 5, 6, and 7 days after vaccination
showed no significant differences between groups (Fig. 4).
Seven days after vaccination, mean body weight changes
of the GCC vaccinated, positive control and negative con-
trol groups were 3.2 ± 0.7 g, 3.7 ± 1.7 g and 3.4 ± 0.8 g, re-
spectively (P = 0.87). The mean body weight change of the
GCC vaccinated group was therefore greater than 60% of
those of the positive and negative control groups.
The mean leukocyte counts 7 days after vaccination of
the GCC vaccinated, positive control and negative con-
trol groups were 5630 ± 1542/μL, 6495 ± 1627/μL, and
5385 ± 1497/μL, respectively, and showed no significant
differences between the three groups (P = 0.37). The
range of leukocyte counts in the GCC vaccinated group
was 4450/μL to 9850/μL, and all values were within a
mean ± 3 SD range.
Discussion
In the present study, the immunogenicity and safety of a
newly developed Tdap vaccine were determined in a
murine model. The new Tdap vaccine showed compar-
able immunogenicity, protection efficacy, and safety with
a commercially available Tdap vaccine.
Fig. 1 Tdap booster vaccine immunogenicity determined by titers of antibodies against pertussis antigens before and after vaccination
Fig. 2 Tdap booster vaccine immunogenicity determined by titers of antibodies against diphtheria and tetanus toxoids before and after vaccination
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The WHO recommends a non-clinical study as well as
a clinical study before approval and implementation of a
new vaccine containing aP antigens [9]. Accordingly,
several non-clinical trials on the immunogenicity, pro-
tection efficacy, and safety of DTaP vaccines have been
reported [10, 11, 16, 17]. However, only a few non-
clinical trials on Tdap vaccines have been reported as
commercially available Tdap vaccines were manufac-
tured using the same aP antigens included in approved
DTaP vaccines [12], and Tdap vaccines were approved
based on clinical trial results [18–20]. Although non-
clinical trials are necessary for Tdap vaccines manufac-
tured by companies that have not previously produced
DTaP vaccines, the methodology of these trials has yet
to be established. In particular, it is essential to deter-
mine whether Tdap vaccines containing lower doses of
diphtheria toxoid and pertussis antigens compared with
DTaP vaccines can induce a boosting effect. We have
previously reported preliminary results from a non-
clinical study of the new GCC Tdap vaccine using a
Fig. 3 Tdap booster vaccine protection efficacy determined by lung Bordetella pertussis colony counts after intranasal challenge test
Fig. 4 Tdap booster vaccine safety assessed by mouse weight gain test
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murine model [8]. In this study, mice received two doses
of DTaP vaccine as primary vaccination followed by a
single dose of Tdap vaccine as booster vaccination, a
method that considered the human vaccination schedule
of four doses of DTaP vaccine and one dose of Tdap
vaccine [8]. Although the new Tdap vaccine showed fa-
vorable immunogenicity and protection efficacy against
B. pertussis intranasal challenge, antibody titers against
pertussis antigens were high even before Tdap booster
vaccination, and inoculated B. pertussis was completely
eradicated within 5 days of intranasal challenge [8].
These results are believed to be a consequence of the
prolonged effect of two shots of DTaP vaccination sup-
plementing the boosting effect of Tdap vaccination. As a
result, primary DTaP vaccination was administered as a
single dose in the present study, and the interval be-
tween the primary and booster vaccinations was ex-
tended from 6 weeks to 12 weeks.
In the present study, anti-PT IgG and anti-FHA IgG
titers significantly increased in the GCC vaccine group
(Group 4) and positive control group (Group 5) after
Tdap booster vaccination, and no significant difference
was observed after booster vaccination between the two
groups. Therefore, the immunogenicity of a Tdap vac-
cine can be determined using one dose of primary DTaP
vaccine followed by one dose of Tdap booster vaccine in
a murine model, and the new GCC Tdap vaccine
showed immunogenicity comparable with a commer-
cially available Tdap vaccine using this strategy. In a pre-
vious non-clinical study of a Tdap vaccine in a murine
model, one dose of primary DTwP vaccine was adminis-
tered followed by one dose of Tdap booster vaccine
12 weeks later [12]. The boosting effect of the Tdap vac-
cine decreased upon reduction of pertussis antigen dose
in the primary DTwP vaccine, and the authors therefore
recommended an increased interval between primary
and booster vaccinations to rule out residual effects of
primary vaccination [12]. In the present study, the anti-
body titers against pertussis antigens, DT and TT tended
to increase after booster vaccination even in the Groups
2 and 3, in which PBS or Td vaccine was administered
as the booster vaccination, although the anti-PT and
anti-FHA IgG titers against pertussis antigens in the
Groups 2 and 3 were lower than those in the Groups 4
and 5. This result could be caused by the prolonged ef-
fects of the primary DTaP vaccination in the Groups 2
and 3. Therefore, the interval between primary and
booster vaccinations should be longer than 12 weeks to
completely exclude the residual effects of the primary
vaccination.
An intranasal challenge test was additionally per-
formed to determine the protection efficacy of the Tdap
vaccine against B. pertussis in the present study, al-
though the WHO recommendations for non-clinical
studies only specify antibody tests [9]. Because B. pertus-
sis was eradicated within 5 days of intranasal infection in
the preliminary study [8], colony counts were deter-
mined 2 and 4 days after infection in the present study.
With the use of a single dose of DTaP vaccine, the bac-
teria were eradicated 7 days after intranasal infection,
2 days later than with two doses. The GCC vaccine
group showed significantly lower CFUs than the positive
control group 2 days after infection, indicating a potent
effect in the early phase. If we consider that the results
of the intranasal challenge test in a murine model are
representative of clinical efficacy in humans [11], the
new GCC Tdap vaccine may be used effectively in the
clinical field. In addition, the new Tdap vaccine showed
comparable results with a commercially available Tdap
vaccine in MWGT and LP test. Therefore, further clin-
ical trials for the new Tdap vaccine may be performed
safely. In mice treated with DTaP vaccine at 25% of the
human dose, inoculated B. pertussis persisted longer
than 9 days after intranasal challenge in the negative
control group injected with normal saline as a booster
vaccination. We thought this dose was sufficiently low
to prevent residual effects of the primary DTaP vaccin-
ation on the boosting response of the Tdap vaccine,
given the 12-week interval between primary and booster
vaccinations; however, an interval longer than 12 weeks
could be appropriate to exclude the residual effects, con-
sidering the results of the immunogenicity assessment.
This study has several limitations. Neither the GCC
nor the commercial Tdap vaccine had a significant effect
on anti-PRN IgG titers. However, significant humoral
immune responses to PT and FHA and a significant pro-
tection efficacy in the intranasal challenge model were
observed in both groups. Although cellular immune re-
sponses also play an important role in the protective im-
munity against B. pertussis [17, 21–23], they were not
measured in the present study. In previous studies, Th1
and Th17 responses were detected after DTwP vaccin-
ation and natural B. pertussis infection, and Th2 re-
sponses were detected after DTaP vaccination [17, 21,
22, 24]. In contrast, some investigators reported Th1-
dominant responses or Th1 and Th2 mixed responses
even after DTaP vaccination [16, 25]. Moreover, cellular
immune responses after booster DTaP or Tdap vaccin-
ation differed according to the type of primary vaccin-
ation in some studies [12, 26]. Therefore, future studies
should determine cellular immune responses elicited by
Tdap booster vaccination. Based on the results of cellu-
lar immune responses of the new Tdap vaccine with a
combination of the results of the present study, clinical
trials should be planned. For in vivo assessment of re-
sidual toxicity of aP antigens, a histamine sensitization
test is recommended [9]. The present study instead used
MWGT and LP test. The histamine sensitization test is
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supposed to be performed using a GCC DTaP vaccine
containing an increased aP antigen dose than the GCC
Tdap vaccine.
Conclusions
In conclusion, a murine model consisting of a single
dose of primary DTaP vaccination followed by a single
dose of booster Tdap vaccination can be applied to non-
clinical studies of Tdap vaccines with an interval longer
than 12 weeks between primary and booster vaccina-
tions. When tested according to this model, the new
GCC Tdap vaccine exhibited comparable immunogen-
icity, protection efficacy, and safety with a commercially
available Tdap vaccine. Future clinical trials using the
new GCC Tdap vaccine can be performed after confirm-
ation of appropriate cellular immune responses in non-
clinical trials.
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